Score Overview
PeriodNet IncomeRevenueScoreGrowthTrendConsistencyGrowthTrendConsistency
1 Year
—
-5.35%
Shrank
—
—
Shrank
—
1 Year
Score—
Net Growth-5.35%
Net TrendShrank
Net Income Consistency—
Rev Growth—
Rev TrendShrank
Revenue Consistency—
5 Years
2.4
-52.91%
40%
—
-100.00%
Never
—
5 Years
Score2.4
Net Growth-52.91%
Net Trend40%
Net Income Consistency—
Rev Growth-100.00%
Rev TrendNever
Revenue Consistency—
Gain Therapeutics Inc fundamental performance
Between 2021 and 2025, revenue declined from $ 164.99K to $ 0.00 and net income went from -$ 13M to -$ 20M. Revenue increased in 0% of the years measured; net income in 40%.
Gain Therapeutics Inc currently holds a 5-year HDB Score of 2.4 out of 10. How the HDB Score is calculated.
Net Income x Stock Price
Historical Returns
| Period | Price | Return |
|---|---|---|
Last Price2026-08-12 | $ 2.12 | — |
1 Year2025-08-12 | $ 1.53 | 38.56% |
5 Years2021-08-12 | $ 7.72 | -72.54% |
All Time2021-03-18 | $ 11.20 | -81.07% |
| Period | Last Price2026-08-12 | 1 Year2025-08-12 | 5 Years2021-08-12 | All Time2021-03-18 |
|---|---|---|---|---|
| Price | $ 2.12 | $ 1.53 | $ 7.72 | $ 11.20 |
| Return | — | 38.56% | -72.54% | -81.07% |
Prices are split & dividend adjusted. All values are reported in USD.
Fundamental Data
| Year | |||
|---|---|---|---|
| 2026 | $ 0.00 | -$ 21M | $ 16M |
| 2025 | $ 0.00 | -$ 20M | $ 20M |
| 2024 | $ 0.00 | -$ 20M | $ 10M |
| 2023 | $ 55.18K | -$ 22M | $ 16M |
| 2022 | $ 140.11K | -$ 17M | $ 20M |
| IPO2021 | $ 164.99K | -$ 13M | $ 36M |
Explore beyond GANX
You're looking at Gain Therapeutics Inc. Members apply the same fundamental framework across all 3,860 companies we cover.
- Every HDB Score — 1, 5, 10, 20 and 30 years, plus all-time
- Revenue and Net Income Consistency for every period
- Rank all 3,860 companies by any metric, not just three
- Filter by sector and currency, and page through the whole list
- Track your holdings in a portfolio
$99/year $149 founding price
Unlock Holder Dashboard30-day money-back guarantee.
